As the patent expiration of Keytruda, the world's top-selling immuno-oncology drug, approaches, competition in the biosimilar development sector is heating up. Samsung Bioepis and Celltrion have both submitted approval applications, while global competitors are also rushing to enter the market. The commercialization of Keytruda biosimilars is expected to significantly contribute to the revenue growth of these companies, drawing considerable market interest.
According to industry sources, MSD's Keytruda (ingredient name: pembrolizumab) generated $31.7 billion in sales last year, accounting for 49% of MSD's total revenue of $65 billion. The U.S. patent is set to expire in December 2028, while the European patent will expire in 2031. Once the patents are lifted, a market worth approximately $46 billion will open for this single product, which is why the biosimilar industry is heavily invested in developing Keytruda alternatives.
In South Korea, Samsung Bioepis and Celltrion are ramping up their commercialization efforts. Samsung Bioepis applied for product approval for its Keytruda biosimilar 'SB27' with the Ministry of Food and Drug Safety in August and with the U.S. Food and Drug Administration (FDA) last month. The company reported that it confirmed the equivalence of primary and key secondary efficacy endpoints in a global Phase 3 clinical trial involving 555 patients across 14 countries in June. At the European Society for Medical Oncology (ESMO) conference last month, it also presented results demonstrating pharmacokinetic equivalence from a Phase 1 trial involving 163 patients with non-small cell lung cancer across four countries. The FDA application covers 18 indications, including melanoma, non-small cell lung cancer, and head and neck cancer.
Celltrion also submitted a product approval application for 'CT-P51' to the Ministry of Food and Drug Safety in August. In a clinical trial involving 228 patients with melanoma who underwent complete resection, pharmacokinetic equivalence with the original drug was confirmed. The company plans to sequentially apply for approvals in major markets, including the U.S., Europe, and Canada.
Meanwhile, foreign companies are also moving quickly. Amgen is conducting a Phase 3 trial for 'ABP 234'. Swiss company Sandoz and German firm Formycon have shifted their strategy to utilize Phase 1 data for approval after halting their comparative Phase 3 trials. This approach is seen as a strategy to expedite their launch by taking advantage of the trend of U.S. and European regulatory agencies relaxing clinical requirements for comparative efficacy in biosimilars. Formycon's 'FYB206', developed in collaboration with India's Zydus Lifesciences, applied for FDA approval on October 13. Chinese company Biotest has also entered a clinical trial that combines Phase 1 and Phase 3 studies.
However, a variable in this landscape is MSD's subcutaneous formulation 'Keytruda Qurex'. While the original Keytruda is administered intravenously, Qurex allows for a quicker administration time through subcutaneous injection. Qurex generated $830 million in sales in the third quarter, accounting for 9.7% of Keytruda's total revenue. The patent for Qurex will remain in effect until 2041.
Currently, most biosimilars under development are in intravenous form. As more patients transition to subcutaneous injections before the patent expiration, the market available for biosimilars will shrink. The extent to which intravenous biosimilars can capture market share is expected to influence future competitive dynamics. Analysts suggest that the competition in the Keytruda market is shifting from a battle between the original and biosimilar drugs to a competition between intravenous and subcutaneous formulations.
Jung Yoon-taek, head of the Pharmaceutical Industry Strategy Research Institute, stated, "MSD's introduction of a subcutaneous formulation using Alteogen technology is a strategy in anticipation of patent expiration. Just as Novo Nordisk focused on Wegovy instead of Saxenda, MSD is likely to concentrate more on the subcutaneous formulation that still has patent protection."
Experts believe that for domestic companies to gain an edge in the global competition, speed of launch and supply chain management will be crucial. Jung emphasized, "Korean bio companies have already proven themselves as first movers in the biosimilar sector through approvals like that of 'Remsima'. Based on this, they need to proactively launch Keytruda biosimilars to establish price competitiveness and secure a global supply chain. A marketing strategy linked with local partners will also be important."
According to industry sources, MSD's Keytruda (ingredient name: pembrolizumab) generated $31.7 billion in sales last year, accounting for 49% of MSD's total revenue of $65 billion. The U.S. patent is set to expire in December 2028, while the European patent will expire in 2031. Once the patents are lifted, a market worth approximately $46 billion will open for this single product, which is why the biosimilar industry is heavily invested in developing Keytruda alternatives.
In South Korea, Samsung Bioepis and Celltrion are ramping up their commercialization efforts. Samsung Bioepis applied for product approval for its Keytruda biosimilar 'SB27' with the Ministry of Food and Drug Safety in August and with the U.S. Food and Drug Administration (FDA) last month. The company reported that it confirmed the equivalence of primary and key secondary efficacy endpoints in a global Phase 3 clinical trial involving 555 patients across 14 countries in June. At the European Society for Medical Oncology (ESMO) conference last month, it also presented results demonstrating pharmacokinetic equivalence from a Phase 1 trial involving 163 patients with non-small cell lung cancer across four countries. The FDA application covers 18 indications, including melanoma, non-small cell lung cancer, and head and neck cancer.
Celltrion also submitted a product approval application for 'CT-P51' to the Ministry of Food and Drug Safety in August. In a clinical trial involving 228 patients with melanoma who underwent complete resection, pharmacokinetic equivalence with the original drug was confirmed. The company plans to sequentially apply for approvals in major markets, including the U.S., Europe, and Canada.
Meanwhile, foreign companies are also moving quickly. Amgen is conducting a Phase 3 trial for 'ABP 234'. Swiss company Sandoz and German firm Formycon have shifted their strategy to utilize Phase 1 data for approval after halting their comparative Phase 3 trials. This approach is seen as a strategy to expedite their launch by taking advantage of the trend of U.S. and European regulatory agencies relaxing clinical requirements for comparative efficacy in biosimilars. Formycon's 'FYB206', developed in collaboration with India's Zydus Lifesciences, applied for FDA approval on October 13. Chinese company Biotest has also entered a clinical trial that combines Phase 1 and Phase 3 studies.
However, a variable in this landscape is MSD's subcutaneous formulation 'Keytruda Qurex'. While the original Keytruda is administered intravenously, Qurex allows for a quicker administration time through subcutaneous injection. Qurex generated $830 million in sales in the third quarter, accounting for 9.7% of Keytruda's total revenue. The patent for Qurex will remain in effect until 2041.
Currently, most biosimilars under development are in intravenous form. As more patients transition to subcutaneous injections before the patent expiration, the market available for biosimilars will shrink. The extent to which intravenous biosimilars can capture market share is expected to influence future competitive dynamics. Analysts suggest that the competition in the Keytruda market is shifting from a battle between the original and biosimilar drugs to a competition between intravenous and subcutaneous formulations.
Jung Yoon-taek, head of the Pharmaceutical Industry Strategy Research Institute, stated, "MSD's introduction of a subcutaneous formulation using Alteogen technology is a strategy in anticipation of patent expiration. Just as Novo Nordisk focused on Wegovy instead of Saxenda, MSD is likely to concentrate more on the subcutaneous formulation that still has patent protection."
Experts believe that for domestic companies to gain an edge in the global competition, speed of launch and supply chain management will be crucial. Jung emphasized, "Korean bio companies have already proven themselves as first movers in the biosimilar sector through approvals like that of 'Remsima'. Based on this, they need to proactively launch Keytruda biosimilars to establish price competitiveness and secure a global supply chain. A marketing strategy linked with local partners will also be important."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.